What type of study is this?

This is a In Vitro Study study (also classified as: Animal Study).

September 20, 2025Cancer Research

Abstract B068: In vitro and in vivo efficacy of the antibody-drug-conjugate (ADC) PB-vcMMAE-5 against human ovarian cancer expressing truncated core 2 O-glycans

View Full Paper

Ask AI

Bookmark

PB-vcMMAE-5 showed substantial tumor growth inhibition in ovarian cancer models, enhancing the efficacy of treatment.
Cytotoxicity assays indicated that PB-vcMMAE-5 effectively reduced tumor volume, while the naked PB-223 antibody had no effect.
In vivo testing in mice revealed a maximum tumor growth inhibition of 109.24% after treatment with varying doses of PB-vcMMAE-5.
Ongoing assessments are expected to further solidify the potential of PB-vcMMAE-5 as a therapeutic candidate for ovarian tumors expressing specific O-glycans.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

In vitro testing demonstrated cytotoxicity in ovarian cancer, with in vivo results indicating significant tumor growth inhibition, suggesting potential for novel immunotherapeutic strategies.

Cite This Study

Tsang et al. (2025) studied this question.

synapsesocial.com/papers/68d469ba31b076d99fa66293 https://doi.org/10.1158/1538-7445.ovarian25-b068

View Full Paper

Ask AI

Bookmark

Implication

In vitro testing demonstrated cytotoxicity in ovarian cancer, with in vivo results indicating significant tumor growth inhibition, suggesting potential for novel immunotherapeutic strategies.

Abstract B068: In vitro and in vivo efficacy of the antibody-drug-conjugate (ADC) PB-vcMMAE-5 against human ovarian cancer expressing truncated core 2 O-glycans

Key Points

Discussion

Implication

Cite This Study

Abstract B068: In vitro and in vivo efficacy of the antibody-drug-conjugate (ADC) PB-vcMMAE-5 against human ovarian cancer expressing truncated core 2 O-glycans

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading